Bibliographical noteFunding Information:
RC received personal fees for speaking engagements and development of educational materials. CB's institution received grant and research support from Pfizer, Novartis, Amgen, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Roche/Genentech, Lilly, Sanofi, Taiho Pharmaceutical, Mylan, Merrimack, Merck, AbbVie, Astellas Pharma, BioMarin, Bristol-Myers Squibb, Daiichi Sankyo, Abraxis Biosciences, AB Science, Asana Biosciences, Medivation, Exelixis, ImClone Systems, LEO Pharma, Millennium, Merck KGaA, Shanghai Henlius Biotech, Polyphor, and PharmaMar. CB was on the advisory board or consulted for, received payment or honoraria, and received support for attending meetings for Boehringer-Ingelheim, GSK, Novartis, Pfizer, Roche/Genentech, Eisai, Bayer, MSD, AstraZeneca, Zodiac, Lilly, Sanofi, and Amgen. MD received grants or contacts to their institution for Pfizer and Lilly; received consulting fees from Radius, G1, AbbVie, H3 Biomedicines, Lilly, Zentalis, Roche, Besins, AstraZeneca, and ROVI; and received payment or honoraria from Nanostring. SI received academic grant funding from the National Institute for Health Research; international research funding from Novartis; consulting fees to their institution from Lilly and Roche; institutional payment or honoraria from Roche; support for attending meetings from Roche and Lilly; and was the chair for the Breast Research Group with the National Cancer Research Institute. RC, AC, and CB were members of the D-CARE Trial Steering Committee; RC and LC were members of the D-CARE biomarker subcommittee and AH was a member of the D-CARE data monitoring and safety committee. AH is on the German Breast Group Independent Data Monitoring Committee (multiple studies), Bristol Myers Squibb (CA2097FL), and Pfizer. All other authors declare no competing interests.
ASJC Scopus subject areas